Beijing’s IOL Agreement Expired 28 June With No Renewal. Our Q2 2026 Calls, Graded.
The device-renewal rulebook appeared in Q2 for stents, not lenses. A quarter of OphthalLogix judgements graded: what held, what stays untested, and the reading we corrected.
Q2 2026 resolved one open question about China’s intraocular-lens market and left another exposed. The machinery for renewing a device volume-based procurement became visible, the coronary-stent second round ran to a full multi-year cycle, while no equivalent scheme was published for lenses; Beijing’s first-wave IOL agreement expired on 28 June, the national wave on 30 June, into that vacuum. This is a quarter graded against its own record: what OphthalLogix judged, what the quarter did, and the one reading we corrected.
The through-line is a single widening distance. A worked renewal template now exists and carries dates; the IOL-specific scheme does not exist at all. That is this cycle’s policy-execution gap in its plainest form, no longer a hypothesis about how renewal might work, but a dated absence. A second development pulled the same way, and it is the one that matters most this quarter: two separate 2026 instruments, the national eye-surgery pricing framework (医保价采函〔2024〕87号 / eye-care service-pricing framework) and the pending version-3.0 case-payment grouping, have converged on the same definition of a ‘complex’ cataract, and that convergence forecloses a reading the market has been carrying about premium lenses.
What we judged, and what the quarter did
We judged that a renewal template would arrive before any IOL-specific scheme; that hospitals would hold at existing selected prices and manage volume down rather than freeze orders or move to non-selected listings; and that any eventual renewal price change would be moderate. The direction held. The first-wave agreements lapsed on schedule, Beijing 28 June, the national and Hunan procurements on 30 June, and no IOL renewal, transitional, or second-round document appeared. On 30 June the national platform issued only a routine listing-maintenance and price-filing notice, under which nationally procured items file no new price: housekeeping, not renewal. Magnitude is where we cannot yet claim to be right, with no scheme to measure against; our estimate of a moderate change is untested. For a reader, the operative model for the interval is a price-hold with volume managed down, not a price cut, until a scheme is published.
Our framework of three coexisting reimbursement regimes, a hard cap with patient top-up, cap-removed proportional payment, and DRG/DIP bundling, went unchallenged through the quarter. It holds. The consequence is unchanged: a single national commercial strategy will misallocate in at least one regime, because the economics of the same lens differ by payment architecture, not by list price.
We treated the coronary-stent second-round renewal as the likeliest reference for an eventual IOL renewal, inquiry-based pricing, volume tied to bid position, and an explicit anti-involution principle. The mechanism read is correct: the second round opened on 20 May, tentative selection results were shown 21–25 May, and the procurement cycle runs to 30 June 2029. Here we record a deliberate omission rather than a claim. Media accounts of the renewal’s headline price change did not agree with one another; several conflated the inquiry benchmark with a final selected price, so we withheld the figure. One specific number we chose not to publish, because we could not yet stand behind it. Rely on the mechanism as the template, not on any single price now circulating for it.
On the provincial unbundling of eye-surgery pricing, the split confirmed as we expected across four provinces. On one point, the correction runs against our own earlier work. We had implied that the framework’s ‘complex’ implantation tier could serve as a cost-recovery channel for premium lenses. It cannot. The ‘complex’ tier is defined by surgical difficulty, a capsular tension ring, and zonular suspension, not by the price of the lens. A premium trifocal implanted in a routine eye is billed at the standard rate. What makes this more than a housekeeping correction is that a second instrument now says the same thing from the opposite side of the payment system: the version-3.0 grouping carves out ‘complex cataract surgery’ as a standalone group on identical grounds, surgical difficulty, lens dislocation and suspension, not lens premium. Pricing and payment have converged on one definition, and it is not the lens. Any cataract model that assumed a premium-recovery channel in the ‘complex’ tier should remove it, on both the pricing side and the grouping side.
We had placed four compliance developments on a single clock: the mandatory cataract surgery standard, the county enforcement directive, the fund audit reaching ophthalmology, and, from 8 June, a 14-ministry anti-corruption work plan (国卫医急函〔2026〕123号) that notably paired a medical-device tax-enforcement drive with a research commitment to direct medical-insurance settlement. That reading held and hardened. Compliance readiness and procurement readiness are one workstream now, not two. The immediate action for an international device manufacturer is a review of distributor tax-compliance exposure; multi-tier IOL distribution sits inside the named risk zone.
What Q3 turns on
One development will decide more than any other: the version-3.0 ophthalmology grouping. The formal scheme had not been released by quarter-end; a standalone group for complex cataract surgery is already confirmed, and release is expected in July, with execution from January 2027. Under bundled payment, the grouping weights are the variable that sets premium-lens economics. The convergence noted above raises the stakes: the same instrument that will price the case has already defined ‘complex’ in a way that excludes the premium lens. Watch the weights.
Key Implications
For market-access and investment teams, the second quarter confirmed that winning a procurement tender is the entry ticket, not the volume. The renewal interval should be modelled as a price-hold with managed volume, not a price cut, until an IOL scheme is published. The unbundling of eye-surgery pricing does not open a premium-lens cost-recovery channel, and because the version-3.0 grouping defines ‘complex’ on the same surgical-difficulty basis, that door is now closed on both the pricing and the payment side; any model that assumed otherwise should be revised. Compliance exposure, distributor tax position in particular, now shares a timeline with procurement. The single item to watch into the third quarter is the ophthalmology grouping in the version-3.0 payment scheme, a rule written centrally, executed locally, on weights not yet visible. That is the policy-execution gap that will define the next quarter.
This content is for informational purposes only and does not constitute legal, regulatory, investment, or medical advice. China’s healthcare policy environment moves quickly; the status of any regulatory development should be verified independently before informing a commercial or compliance decision. OphthalLogix Intelligence accepts no liability for decisions made in reliance on this content. intelligence@ophthallogix.com · www.ophthallogix.com